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control groups (placebo, Nitroglycerin or Dobutamine plus conventional treatment).
The comprehensive evaluation of relative risk for 30- (RR 1.004, 95% CI 0.995-
1.014) and 180-day (RR 1.006, 95% CI 0.988-1.024) mortality showed no signiﬁcant
differences between two groups. There was no signiﬁcant difference in the mortality
rate between the group of less than 30-day (RR 1.015, 95% CI 0.989-1.041) and the
group of 90-day (RR 1.011, 95% CI 0.974-1.048). Moreover, there was also no
signiﬁcant difference found between the 30- (RR 1.011, 95% CI 0.998-1.024) and 90-
day readmission rate (RR 1.049, 95% CI 0.963-1.144). In the meantime, cumulative
meta-analysis demonstrated no statistically signiﬁcant beneﬁts on improving the
mortality rate with Nesiritide administration in ADHF.
Conclusions: Neither mortality nor readmission to the hospital was reduced or
increased for any length of follow-up after treatment with Nesiritide in addition to
conventional treatment in adult patients with ADHF. Further investigation on the
mortality beneﬁt of Nesiritide treatment in patients with ADHF is unlikely to yield a
positive result. Although Nesiritide could reduce dyspnea to some extent if added to
conventional treatment, strict attention should be paid on the pharmaceutical indica-
tion for patient with ADHF.
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Effects of Ginkgo biloba extract in combination with anti-platelet drugs on
platelet aggregation: a meta-analysis of randomized controlled trials
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Objectives: The effects of Ginkgo biloba extract (GBE) in combination with anti-
platelet drugs on platelet aggregation were not clear. The objective of this meta-
analysis is to elucidate the effects of GBE in combination with anti-platelet drugs on
platelet aggregation and bleeding time in order to provide reference proof for rational
use of them.
Methods: Randomized controlled trails (RCTs) were searched from PubMed, Spring
Ling, Biosis Previews and The Cochrane without restriction of year and language.
RCTs involving the combination of GBE with anti-platelet drugs and assessing the
effects of the combination on platelet aggregation or bleeding time were included.
Collagen-induced platelet aggregation, ADP-induced platelet aggregation and
bleeding time were used as analysis indexes. A meta-analysis was performed by
RevMan 5.0.
Results: Six RCTs with 316 participants were included in the meta-analysis. The
combination of GBE with anti-platelet drugs has inhibitory trend on ADP-induced
platelet aggregation [MD¼-3.45, 95% CI (-7.39, 0.50), P¼0.09], and no inhibitory
effect on collagen-induced platelet aggregation [MD¼-0.56, 95% CI (-3.91, 2.80),
P¼0.74]. No difference of prolonged bleeding time between the combination and anti-
platelet drugs used alone was noted [MD¼0.39, 95% CI (-0.09, 0.86), P¼0.11].
Conclusions: The meta-analysis suggested that compared with anti-platelet drugs
used alone, the combination of GBE with anti-platelet drugs here may not be sig-
niﬁcant inhibition on platelet aggregation, but in view to fewer studies included, the
conclusion is prudent to be applied to clinical practice and need. Larger scale
multicenter randomized controlled trial to validate in the future.
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Objectives: Elevated serum inﬂammatory markers, such as high sensitivity C-reactive
protein (hs-CRP), were regarded as risk factors for cardiovascular events. Sodium
tanshinone IIA sulfate (STS), an extract of the root of Salvia miltiorrhiza, has been
proved to have anti-inﬂammatory effects in basic researches, but the evidence sup-
porting such efﬁcacy in Coronary Heart Disease (CHD) patients remains unclear. The
purpose of this study was to access the effects of STS on elevated serum hs-CRP and
other inﬂammatory markers in patients with CHD.
Methods: This is a prospective randomized open-label blinded end point (PROBE)
designed trial. The study protocol has been approved by Ethics Committee of Xiyuan
Hospital, China Academy of Chinese Medical Sciences (2012XL022-2). 72 conﬁrmed
CHD inpatient of unstable angina (UA) or acute non-ST segment elevation myocardial
infarction (NSTEMI) with elevated serum hs-CRP were enrolled and randomized 1:1
into the control or experimental group. The control group received standard medi-
cation for treatment of CHD including 20mg atorvastatin while the experimental
group additionlly received intravenously a daily 80mg dose of STS for 14 days. The
primary outcome was serum Hs-CRP level. The secondary outcomes were other
serum imﬂammatory factors and improvement in symptoms of angina as well as side
effects. Outcome parameters were assessed blindly to treatment allocation at baseline,
immediately after the 14-day treatment period and at 30 days after the treatment
stopped.
Results: After 14-day treatment, the level of hs-CRP were signiﬁcantly reduced
(6.363.42 mg/l to 2.835.94 mg/l and 5.752.39 mg/l to 1.024.31 mg/l) in both
the experimental and control groups; The reduction of the experiment group was moreC206 JACC Vol 64/16/Suppl C j October 16–1signiﬁcant than that of the control group (P¼0.0485, IQR: 2.9(1.3, 6.05) vs 1.54
(-1.45, 3.51) mg/dL), so as the pecent change (P¼0.0114, media: 71.75% vs 30%).
The reduction in monocyte chemotactic protein 1 (MCP-1) and soluble CD40 ligand
(sCD40L) of the experiment group was more signiﬁcant than that of the control group
(P¼0.013 and P¼0.0454, respectively). At 30 days after the treatment stopped, the
level of MCP-1 had greater reduction in the experiment group compared with that of
the control group (P¼0.0253, 54.6447.38 vs 30.7239.82 pg/dL). Other inﬂam-
matory markers had no signiﬁcant reduction between groups. In addition, STS also
signiﬁcantly improved angina symptom at the two time-points after treatment. There
were no serious adverse events occurred.
Conclusions: On the background of statin therapy, a daily 80mg dose of STS intra-
venously for 14 days further reduced levels of circulating inﬂammatory markers of hs-
CRP, sCD40L and MCP-1 in UA/NSTEMI patients. Together, our study suggested
that STS could be used as a complementary treatment in CHD patients with enhanced
inﬂammatory reaction.
(Clinical Trial Registration number: ChiCTR-TRC-12002361).
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Beneﬁcial effect of Qishen Capsule on serum resistin levels in unstable angina
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Objectives: Resistin is a novel adipokine that is involved in inﬂammatory conditions
and atherosclerosis. In this study we aimed to investigate the beneﬁcial effect of
Qishen Capsule on serum resistin levels in unstable angina.
Methods: 154 unstable angina patients were randomly assigned to two groups. One
group (regular group) received oral aspirin, clopidogrel, beta-blockers, and heparin;
the other group (combined group) received regular treatment and Qishen Capsule
(three pills, third per day). Study drugs were administered for six weeks in both
groups. Resistin levels were measured using ELISA at the beginning of the study and
at study end. Patients were evaluated monthly for blood pressure, fasting serum
glucose levels and adverse events.
Results: Both therapeutic regimens reduced resistin levels; combined treatment group
resulted in a greater decrease in resistin levels (4.171.52 ng/mL to 2.050.92 ng/
mL) when compared with regular treatment group (3.951.46 ng/mL to 2.390.91
ng/mL) (P<0.05). None of the patients experienced adverse events.
Conclusions: Results showed that combined treatment group resulted in a greater
reduction in resistin levels than regular treatment group alone.
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Objectives: To nvestigate whether it is the same by application of rosuvastatin 20mg
as atorvastatin 40mg on effectiveness and safety in patients with acute myocardial
infarction (AMI).
Methods: A total of 130 AMI patients enrolled in the study, all patients underwent
standardized treatment as guidelines recommend. After admission they were seperated
into two groups: atorvastatin 40mg/day group and and rosuvastatin 20mg/day group,
and wiould continue to take the medicine for 30 days. The primary end point was the
reduction of serum LDL-c levels, all-cause mortality, re-AMI, readmission rate within
30 days. Secondary endpoint were serum transaminases, bilirubin, serum creatinine,
urine protein.
Results: There was no signiﬁcant difference between the two groups (0.321.36,
0.401.13, P¼0.737) about the reduction of serum LDL-c levels and primary clinical
endpoint of all-cause mortality (P¼0.699), the incidence of re-AMI, readmission rate
within 30 days was lower in rosuvastatin group than in atorvastatin group (P¼0.005,
0.018, respectively). There is no no signiﬁcant difference on alanine aminotransferase
and total bilirubin between the two groups. However, the urinary protein levels
increased more in rosuvastatin group than in atorvastatin group (0.100.03 vs
0.170.05, P¼0.009), while serum creatinine levels had the same trend (80.329.6 vs
101.766.9, P¼0.030). After multivariate analysis, it is not statin used but BNP
levels, which was independent risk factors affect the prognosis.
Conclusions: Compared with atorvastatin 40mg/day, rosuvastatin 20mg/day can
reduced re-AMI, readmission rate within 30 days. However, it increased urinary
protein levels and elevated serum creatinine levels. So overall all-cause death,
myocardial infarction again, readmission rates did not differ between the two groups.
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Objectives: To investigate the current status of thromboembolism risk and antith-
rombotic treatment in very elderly patients(age80) with nonvalvular atrial9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
ﬁbrillation(NVAF) and further to provide the suggests for choosing reasonable ther-
apeutic schedule of these patients.
Methods: A total of 319 very elderly patients with nonvalvular atrial ﬁbrillation in
eight Department of Grade III hospitals was enrolled during May 2012 to
September 2013. The status of antithrombotic treatment was observed and a
follow-up of three to six months was given. The patients were divided into warfarin
group, antiplatelet group (aspirin or clopidogrel), dual antiplatelet group, warfarin
combined with antiplatelet group, new oral anticoagulants group (dabigatran) and
no antithrombotic group. Inﬂuential factors of antithrombotic treatment, main
terminal events (including bleeding, ischemic events and death) and its affecting
factors were analyzed.
Results: There were 192 men (60.20%) and 127 women (39.80%) involved in the
study and the average age was (84.663.54) years old. 41 patients used warfarin
anticoagulant therapy alone, 158 patients used antiplatelet therapy (aspirin or clo-
pidogrel) alone, 24 used dual antiplatelet, 7 patients used warfarin combined with
aspirin therapy, 7 patients used new oral anticoagulants therapy and 82 patients
were without any of antithrombotic therapies. According to CHADS2 index, there
were 314 patients suggested to use warfarin and the real percentage of using
warfarin was 15.29 %( 48/314). Of the total patients receiving warfarin, the ratio of
monitoring the international normalized ratio (INR) was 79.17 %( 38/48). The
average level of INR was (1.850.53).And patients’ INR between 1.6-2.5 were only
22 cases (57.89%). During the follow-up visits, 319 very elderly patients were
observed. The main terminal events were 90 cases (28.21%), while the bleeding,
ischemic events and death are 26(8.15%), 23 (7.21%) and 41 (12.85%) respectively.
The bleeding and ischemic events of the antithrombotic group is 2 (3.64%) and 3
(5.45%).
Conclusions: Warfarin is underused in very elderly patients with NVAF who had
indications of anticoagulation. And the ratio of targeted INR is not enough. The main
cause of non-anticoagulation. Is worring about bleeding. The antithrombotic group has
lower rate of bleeding and ischemic events. Therefore, the assessment of the risk of
thromboembolism in very elderly patients and the management of anticoagulant
therapy should be strengthened.
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Clinical efﬁcacy of pitavastatin in treating hypercholesterolemia combined with
chronic heart failure in 24 cases
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Objectives: Pitavastatin is the most reccardiovasculartly approved statin which is
regarded as “superstatins”. This clinical trial was designed to investigate the efﬁcacy
of pitavastatin in treating hypercholesterolemia combined with chronic heart failure.
Methods: Forty-nine patients with hypercholesterolemia combined with chronic heart
failure were divided into the two groups randomly by the blind random method. The
observation group (24 patients) received pitavastatin while the control group (25pa-
tients) received atorvastatin. Both of the two groups received basic therapy of chronic
heart failure including digoxin, Katlex and spironolactone. After a 8-week treatment,
the total cholesterol(TC), low density lipoprotein cholesterol(LDL-C), triglycer-
ides(TG), high density lipoprotein cholesterol(HDL-C) were compared between the
two group.
Results: After treatment the decrease degree of TC and LDL-C in the two groups had
statistical differences (P<0.05).However, TG and HDL-C had no statistical differ-
ences (P>0.05). The reaching standard rate of the LDL-C level and the occurrence
rates of adverse reaction in the two groups had no statistical differences (P>0.05).
Conclusions: Pitavastatin has signiﬁcant effect in treating hypercholesterolemia
combined with chronic heart failure, which can reduce the TC, LDL-C levels, with
low rate of occurrence of adverse reactions. The effect of pitavastatin on the
improvement of chronic heart failure needs more investigation.
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Objectives: This study focued on the efﬁcacy of varenicline and the safety of the
combination of two drugs by investigating the patients who were given clopidogrel
and varenicline with CAD undergoing PCI.
Methods: Eligible smoking patients in hospital, with CAD undergoing PCI were
consecutively included. All patients received aspirin (100 mg/day) and clopidogrel
(loading dose 300mg, followed by 75 mg/day). On 3 day after received clopidogrel
75mg/day, patients will be randomized to receive either associated varenicline or
without varenicline for 14 days. Blood samples will be collected before rendered
clopidogrel, on day 1 before associated varenicline, and on 14 day after associated
varenicline. Clopidogrel effect will be tested by measuring platelet phosphorylated-
VASP expressed as a platelet reactivity index (PRI). All patients were followed 6
months and they were documented smoking ceased rates, concomitant medication and
adverse events.JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CResults: The statistic comparison of the baseline data at admission in two groups
showed no signiﬁcant differences. In the conventional therapy group, PRI was
80.085.60%, 55.2114.87% and 43.0113.59% respectively at the three time. In
varenicline group, PRI was 79.945.18%, 53.7414.47% and 42.1811.27%
respectively at the three time. There was no signiﬁcant difference between the two
groups. The comparison of smoking ceased rates of two groups after 6 months: The
smoking cessation rate was 64.91% in the varenicline group. The smoking cessation
rate was 34.48%. The smoking cessation rate of the varenicline group was higher than
the control group (P<0.010). The data of eGFR were similar in the 2 groups. The
adverse events in varenicline group were higher than in conventional therapy group.
However, there was no signiﬁcant difference between the 2 groups. The serious
adverse events were identical between the 2 groups.
Conclusions: The rate of smoking cessation of varenicline was signiﬁcantly improved
in patients with CAD in periprocedure of PCI. Clopidogrel can be safely administrated
with varenicline without the need for dose adjustment.Cardiac Rehabilitation
Rehabilitation Functional Assessment
GW25-e0727
Relationship between exercise induced elevation of left ventricular ﬁlling
pressure estimated by E/e’ ratio and exercise intolerance in patients with atrial
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Objectives: Elevated left ventricular ﬁlling pressure (LVFP) is an important cause of
exercise intolerance in patients with atrial ﬁbrillation (AF). Exercise stress echocar-
diography could assess LVFP during exercise. The objective of this study was to
investigate the relationship between exercise induced elevation of LVFP estimated by
the ratio of early diastolic mitral inﬂow velocity (E) to early diastolic mitral annular
velocity (e’) and exercise capacity.
Methods: This study included 86 consecutive patients (48 men and 38 women;
mean age 64.69.2 years) with non-valvular AF and normal left ventricular systolic
function (left ventricular ejection fraction 50%). All patients underwent a symp-
tom-limited cardiopulmonary exercise test (CPET). Doppler echocardiography was
performed both at rest and immediately after exercise. Five consecutive measure-
ments of E and e’ were taken and averaged. E/e’ ratio was calculated. Elevated
LVFP was deﬁned as E/e’>9, and patients with elevated LVFP at rest were
excluded.
Results: Patients were classiﬁed into two groups according to LVFP estimated by E/e’
ratio after exercise: 64 (74.4%) with normal LVFP and 22 (25.6%) with elevated
LVFP after exercise. As compared with the patients with normal LVFP, the ones with
elevated LVFP after exercise had signiﬁcantly lower VO2 peak (22.02.6
vs 26.33.7 mL/min/kg, P<0.001), lower anaerobic thresbold (20.12.8 vs
25.74.0mL/min/kg, P<0.001), and shorter exercise time duration (6.20.9
vs 7.11.4min, P<0.001). Multivariate analysis identiﬁed 3 signiﬁcant variables that
are predicative of VO2 peak: age (r¼-0.412, P<0.001), gender (26.54.1 and
23.62.9mL/min/kg for male and female separately, P<0.001) and E /e’ after exercise
(r¼-0.607, P<0.001).
Conclusions: Elevated LVFP estimated by E/e’ ratio after exerceise is independently
associated with reduced exercise capacity. Exercise stress echocardiography could be
a useful diagnostic test for early diastolic dysfunction in AF patients.
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Objectives: To analyze variables (VO2/kg peak, VE/VCO2 nadir and VE/VCO2
slope) in cardiopulmonary exercise testing (CPET) among Chinese patients with
coronary artery disease (CAD) and to aid in developing more effective rehabilitation
programs.
Methods: This study was carried out in a cross-sectional observational way, and it
enrolled totally 38 CAD patients (30 have been treated by PCI and/or CABG) in
Guangdong General Hospital Cardiac Research Institute from November 1st, 2013 to
January 30th, 2014. After consent and clear of contraindications, every patient un-
derwent a CPET*, and patients were encouraged to exercise with maximal efforts. Aardiac Rehabilitation C207
